- Previous Close
0.0700 - Open
0.1926 - Bid 0.1610 x 10000
- Ask 0.1849 x 400
- Day's Range
0.1455 - 0.2380 - 52 Week Range
0.0640 - 12.8000 - Volume
1,160,483,658 - Avg. Volume
8,830,312 - Market Cap (intraday)
25.823M - Beta (5Y Monthly) -0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
www.cero.bio8
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: CERO
View More
Performance Overview: CERO
Trailing total returns as of 2024-11-11, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CERO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CERO
View MoreValuation Measures
Market Cap
10.52M
Enterprise Value
18.46M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-45.28%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.75M
Diluted EPS (ttm)
-1.1900
Balance Sheet and Cash Flow
Total Cash (mrq)
3.65M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
14.46M